29 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
7 May 24
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
7:03am
and Development Expenses: Research and development (R&D) expenses for the three months ended March 31, 2024, were $49.6 million, compared to $48.6 million … and clinical expense, respectively. We also saw increases of $0.7 million and $0.7 million from consulting and R&D cost sharing, respectively
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
27 Feb 24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
7:04am
: Research and development (R&D) expenses for the year ended December 31, 2023 were $189.6 million, compared to $172.7 million for the year ended December
8-K
EX-99.1
s0lgqoo8c8ag ja
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
epwz4237p4yz8 581z
9 Aug 23
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
m0q1bovgphh3ycuf 9l
9 Aug 23
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
7:03am
8-K
EX-99.2
mxbjyjczy4xs826k0
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.1
5cq7nwb9adfqrg qh1hy
10 May 23
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
7:04am
8-K
EX-99.2
onlogt v2v1jao1nt1
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
EX-99.2
kd6y vfpe
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am
8-K
EX-99.1
in2lg7 4ej2n5a1x47nj
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am